CMS: Private insurance spending to increase in 2023, 2024; slow in 2025 onward
(By Rylee Wilson for Becker’s Hospital Review) CMS is projecting a 7.7 percent increase in private health insurance spending in
Read More
CMS
The current Medicare Advantage payment structure results in overpayments
Current research states that the millions of beneficiaries in traditional Medicare who have switched to Medicare Advantage plans have lower
Read MoreInflation Reduction Act Continues to Lower Out-of-Pocket Prescription Drug Costs for Drugs with Price Increases Above Inflation
(Source – cms.gov/newsroom) A continuing key priority of the Biden-Harris Administration is lowering prescription drug costs. Today, the Department of
Read MoreWeight loss drugs and CMS coverage: Why all eyes are on Medicare
(By Rylee Wilson for Becker’s Hospital Review) New GLP-1 drugs to treat diabetes and obesity can be expensive, and most
Read MoreThe Facts About Medicare Spending
(Source – The Kaiser Family Foundation Published June 2023) Medicare provides health insurance coverage for more than 65 million people,
Read MoreWhy some physicians are breaking up with Medicare
(By Riz Hatton for Becker’s Hospital Review) Sixty-five percent of physicians plan to continue treating Medicare and Medicaid patients, according
Read MoreFor many who use power wheelchairs, CMS decision just made seat elevation much less expensive
(By Kerry Dooley Young for STAT) For years, patients and medical groups have advocated for Medicare to cover wheelchairs with
Read MoreMedicare Advantage star ratings decline will cost CVS Health up to $1B in revenue
(By Jakob Emerson for Becker’s Hospital Review) CVS Health is expecting Aetna’s operating income to decrease by up to $1
Read MoreCMS: Dual-eligible Medicare Advantage members less likely to receive cancer screenings, mental healthcare
(By Rylee Wilson for Becker’s Hospital Review) Individuals who are dually eligible for Medicare and Medicaid had lower scores on
Read MoreHow Medicare’s Aduhelm decision revived old questions about new drugs
(By Kerry Dooley Young for STAT) Medicare’s decision to withhold coverage for Biogen’s Aduhelm despite the Food and Drug Administration’s
Read More